Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore Holdings plc (Nasdaq: IMCR) has appointed Travis Coy as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. Coy transitions from his role as Non-Executive Director, which he held since September 2019, to become an Executive Officer.
Coy brings over 20 years of experience from Eli Lilly and Company, where he most recently served as Vice President, Head of Transactions and M&A, Corporate Business Development. His previous roles at Eli Lilly included leading business development for oncology and cardiometabolic diseases, financial leadership of the oncology business unit, Director of Investor Relations, and Director of Corporate Finance and Investment Banking.
The appointment leverages Coy's deep knowledge of Immunocore's operations and science, gained during his five-year tenure as a Non-Executive Director, to support the company's mission in delivering transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases.
Immunocore Holdings plc (Nasdaq: IMCR) ha nominato Travis Coy come Vicepresidente Esecutivo (EVP), Direttore Finanziario e Responsabile dello Sviluppo Aziendale, con effetto dal 1 gennaio 2025. Coy passa dal suo ruolo di Direttore Non Esecutivo, che ricopriva dal settembre 2019, a diventare un Direttore Esecutivo.
Coy porta con sé oltre 20 anni di esperienza in Eli Lilly and Company, dove ha ricoperto l'ultimo incarico come Vicepresidente, Responsabile delle Transazioni e delle Fusioni e Acquisizioni, Sviluppo Aziendale Corporate. I suoi ruoli precedenti in Eli Lilly includevano la guida dello sviluppo aziendale per oncologia e malattie cardiometaboliche, leadership finanziaria dell'unità oncologica, Direttore delle Relazioni con gli Investitori e Direttore della Finanza Aziendale e della Banca d'Investimento.
La nomina sfrutta la profonda conoscenza di Coy delle operazioni e della scienza di Immunocore, acquisita durante i suoi cinque anni di esperienza come Direttore Non Esecutivo, per supportare la missione dell'azienda nel fornire farmaci immunomodulatori trasformativi per il cancro, le malattie infettive e le malattie autoimmuni.
Immunocore Holdings plc (Nasdaq: IMCR) ha nombrado a Travis Coy como Vicepresidente Ejecutivo (EVP), Director Financiero y Jefe de Desarrollo Corporativo, con efecto a partir del 1 de enero de 2025. Coy pasa de su rol como Director No Ejecutivo, que ocupó desde septiembre de 2019, a convertirse en un Oficial Ejecutivo.
Coy aporta más de 20 años de experiencia en Eli Lilly and Company, donde se desempeñó más recientemente como Vicepresidente, Jefe de Transacciones y Fusiones y Adquisiciones, Desarrollo Empresarial Corporativo. Sus roles anteriores en Eli Lilly incluyeron la dirección del desarrollo empresarial para oncología y enfermedades cardiometabólicas, liderazgo financiero de la unidad de negocio de oncología, Director de Relaciones con Inversores y Director de Finanzas Corporativas y Banca de Inversión.
La designación aprovecha el profundo conocimiento de Coy sobre las operaciones y la ciencia de Immunocore, adquirido durante sus cinco años como Director No Ejecutivo, para apoyar la misión de la empresa en la entrega de medicamentos inmunomoduladores transformadores para el cáncer, enfermedades infecciosas y enfermedades autoinmunes.
이뮤노코어 홀딩스 plc (Nasdaq: IMCR)가 트래비스 코이를 집행 부사장(EVP), 최고 재무 책임자(CFO) 및 기업 개발 책임자로 임명하여 2025년 1월 1일부터 업무를 시작합니다. 코이는 2019년 9월부터 비상임 이사로 맡아온 역할에서 집행 임원으로 전환합니다.
코이는 엘리 릴리 앤 컴퍼니에서의 20년 이상의 경험을 보유하고 있으며, 최근에는 부사장으로서 거래 및 인수합병(M&A) 및 기업 사업 개발을 담당했습니다. 엘리 릴리에서의 이전 역할로는 종양학 및 심장대사 질환에 대한 사업 개발, 종양학 비즈니스 유닛의 재무 리더십, 투자자 관계 이사, 기업 재무 및 투자은행 이사가 포함됩니다.
이번 임명은 코이가 비상임 이사로서 5년 동안 습득한 이뮤노코어의 운영 및 과학에 대한 깊은 이해를 활용하여 회사가 암, 감염병 및 자가면역 질환을 위한 혁신적인 면역 조절 약물을 제공하는 미션을 지원합니다.
Immunocore Holdings plc (Nasdaq: IMCR) a nommé Travis Coy en tant que Vice-Président Exécutif (EVP), Directeur Financier et Responsable du Développement Corporatif, à compter du 1er janvier 2025. Coy passe de son rôle de Directeur Non Exécutif, qu'il a occupé depuis septembre 2019, à celui d'Agent Exécutif.
Coy apporte plus de 20 ans d'expérience d'Eli Lilly and Company, où il a récemment occupé le poste de Vice-Président, Responsable des Transactions et des Fusions et Acquisitions, Développement Commercial Corporatif. Ses rôles précédents chez Eli Lilly incluaient la direction du développement commercial pour l'oncologie et les maladies cardiométaboliques, le leadership financier de l'unité commerciale oncologie, Directeur des Relations Investisseurs et Directeur de la Finance d'Entreprise et de la Banque d'Investissement.
Cette nomination s'appuie sur la profonde connaissance de Coy des opérations et de la science d'Immunocore, acquise au cours de ses cinq années en tant que Directeur Non Exécutif, pour soutenir la mission de l'entreprise de fournir des médicaments immunomodulateurs transformateurs pour le cancer, les maladies infectieuses et les maladies auto-immunes.
Immunocore Holdings plc (Nasdaq: IMCR) hat Travis Coy zum Executive Vice President (EVP), Chief Financial Officer und Leiter der Unternehmensentwicklung ernannt, mit Wirkung zum 1. Januar 2025. Coy wechselt von seiner Rolle als Non-Executive Director, die er seit September 2019 inne hatte, zu einem Executive Officer.
Coy bringt über 20 Jahre Erfahrung von Eli Lilly and Company mit, wo er zuletzt als Vice President, Leiter der Transaktionen und M&A, Corporate Business Development tätig war. Zu seinen früheren Positionen bei Eli Lilly gehörten die Leitung von Geschäftsentwicklungen für Onkologie und kardiometabolische Erkrankungen, die finanzielle Leitung der Onkologie-Geschäftseinheit, Director of Investor Relations sowie Director of Corporate Finance und Investment Banking.
Die Ernennung nutzt Coys tiefes Wissen über die Abläufe und die Wissenschaft von Immunocore, das er während seiner fünfjährigen Amtszeit als Non-Executive Director erworben hat, um die Mission des Unternehmens zu unterstützen, transformative immunmodulierende Medikamente für Krebs, Infektionskrankheiten und Autoimmunerkrankungen bereitzustellen.
- Appointment of CFO with extensive 20-year pharmaceutical industry experience
- New CFO brings significant M&A and business development expertise
- Internal candidate with 5 years of company knowledge as Non-Executive Director
- Strong financial and oncology business leadership background
- None.
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Executive Officer, transitioning from his role of Non-Executive Director that he assumed in September 2019.
Travis brings with him over 20 years of experience working at Eli Lilly and Company, where his most recent role was Vice President, Head of Transactions and M&A, Corporate Business Development. Prior to this role, Travis held a variety of roles, at Eli Lilly, of increasing responsibility across finance and business development, including leading business development for oncology and cardiometabolic diseases, financial leadership of the oncology business unit, Director of Investor Relations, and Director of Corporate Finance and Investment Banking. He started his career as a chemist in Lilly’s research laboratories. Travis holds an MBA from the Ross School of Business at the University of Michigan and a BS in Chemistry from Rose-Hulman Institute of Technology.
"I am delighted to welcome Travis to the Executive team," said Bahija Jallal, Chief Executive Officer of Immunocore. “Having served as a Non-Executive Director for 5 years, his deep knowledge of our company and science will be invaluable in his new role as we continue delivering on our mission to transform outcomes for patients.”
“I want to thank Travis for his service on the Board of Immunocore, and in particular his leadership on the Audit Committee,” said Professor Sir John Bell, Chairman of the Board of Immunocore. “I look forward to continuing working with him in his CFO role.”
"I am excited to transition from my position as a Board member of Immunocore to now lead the Finance and Corporate Development functions," said Travis Coy, Immunocore's new Chief Financial Officer. "I look forward to partnering with the other members of the Executive team to deliver transformative medicines to patients with cancer, infectious diseases and autoimmune diseases with our differentiated platform and strong financial base."
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the ability of the Company’s ImmTAX platform to address a broad range of cancers, infectious diseases and autoimmune diseases; and the Company’s ability to deliver transformative medicines to patients. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company’s business, financial position, strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; Immunocore’s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of health epidemics or pandemics, war in Ukraine, the conflict in the Middle East or global geopolitical tension; Immunocore’s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore’s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore’s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore’s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
When does Travis Coy start as CFO of Immunocore (IMCR)?
What was Travis Coy's previous role at Immunocore (IMCR)?
What experience does Travis Coy bring to Immunocore (IMCR)?
What therapeutic areas does Immunocore (IMCR) focus on?
